A study looking at palbociclib, letrozole, trastuzumab and tucatinib before surgery for breast cancer (3-Pillars Study)

This study is looking at palbociclib, letrozole, trastuzumab and tucatinib before surgery for post menopausal women with a newly diagnosed breast cancer.

It is open to women whose breast cancer has:

• receptors for the oestrogen and progesterone hormones (hormone receptor positive)

• a large number of the human epidermal growth factor receptor (HER2 positive)